Testosterone and its metabolites: differential associations with cardiovascular and cerebrovascular

来源 :亚洲男性学杂志(英文版) | 被引量 : 0次 | 上传用户:yangmingli1213
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
As men grow older, circulating testosterone declines while the incidence of cardiovascular disease increases. Thus, the role of sex hormones as biomarkers, and possibly contributing factors to clinical manifestations of cardiovascular disease in the increasing demographic of aging men, has attracted considerable interest. This review focuses on observational studies of endogenous androgens, namely circulating testosterone and dihydrotestosterone, which have examined their associations with cardiovascular events such as myocardial infarction and stroke. Studies which have examined the associations of endogenous estrogens, namely circulating estradiol, with these outcomes are also discussed. In large prospective cohort studies of predominantly middle-aged and older men, lower circulating testosterone consistently predicts higher incidence of cardiovascular events. Of note, both lower circulating testosterone and lower dihydrotestosterone are associated with higher incidence of stroke. These associations are less apparent when myocardial infarction is considered as the outcome. Results for estradiol are inconsistent. Lower circulating testosterone has been shown to predict higher cardiovascular disease-related mortality, as has lower circulating dihydrotestosterone. It is possible that the relationship of circulating androgens to cardiovascular events or mortality outcomes may be U-shaped rather than linear, with an optimal range defining men at lowest risk. Epidemiological studies are observational in nature and do not prove causality. Associations observed in studies of endogenous androgens need not necessarily translate into similar effects of exogenous androgens. Rigorous randomized controlled trials are needed to clarify the effects of testosterone treatment on cardiovascular risk in men.
其他文献
MicroRNAs (miRNAs) are considered to be involved in the pathogenic initiation and progression of chronic nonbacterial prostatitis (CNP);however,the comprehensive expression profile of dysregulated miRNAs,relevant signaling pathways,and core machineries in
In the present study, we evaluated the impact of sperm origins and concentration on the clinical outcomes of intracytoplasmic sperm injection (ICSI) cycles. A total of 1201 ICSI cycles were retrospectively analyzed for male azoospermia or oligozoospermia
The epithelium of the human epididymis maintains an appropriate luminal environment for sperm maturation that is essential for male fertility.Regional expression of small noncoding RNAs such as microRNAs contributes to segment-specific gene expression and
Calpain activation contributes to hyperglycemia-induced endothelial dysfunction and apoptosis.This study was designed to investigate the role of calpain inhibition in improving diabetic erectile dysfunction (ED) in mice.Thirty-eight-week-old male C57BL/6J
Although elevated prolactin levels have been shown to inhibit penile erection,the relationship between prolactin and erection of the penile tip or base has not been extensively researched.We therefore investigated the prolactin\'s effects on erection of
Androgen receptor (AR),a hormonal transcription factor,plays important roles during prostate cancer progression and is a key target for therapeutic interventions.While androgen-deprivation therapies are initially successful in regressing prostate tumors,t
The stromal antigen 3 (STAG3) gene,encoding a meiosis-specific cohesin component,is a strong candidate for causing male infertility,but little is known about this gene so far.We identified STAG3 in patients with nonobstructive azoospermia (NOA) and normoz
Prostate cancer is characterized by bone metastases and difficulty of objectively measuring disease burden.In this context,cell-free circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) quantitation and genomic profiling afford the ability to no
Despite impressive survival benefits with immunotherapy in patients with various solid tumors,the full potential of these agents in prostate cancer has yet to be realized.Sipuleucel-T demonstrated a survival benefit in this population,indicating that pros